Balance Sheet

Cash Flow Statement

Acquisitions Amortization Amortization Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Cash Change in Intangibles Change in Intangibles Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Amortization - Deferred Charges Cost of Revenue EBIAT Gross Profit Long-Term Debt Issuances Long-Term Debt Repayments Non-Current Receivables Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Outstanding Shares Outstanding Short-Term Debt repayments

Trinity Biotech (TRIB) Long-Term Debt Issuances (2020 - 2022)

Trinity Biotech's Long-Term Debt Issuances history spans 3 years, with the latest figure at $63000.0 for Q4 2022.

On a quarterly basis, Long-Term Debt Issuances rose 103.57% to $63000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $78.3 million, a N/A change, with the full-year FY2025 number at $15.0 million, down 50.29% from a year prior.
Long-Term Debt Issuances hit $63000.0 in Q4 2022 for Trinity Biotech, down from $80.0 million in the prior quarter.
Over the last five years, Long-Term Debt Issuances for TRIB hit a ceiling of $80.0 million in Q1 2022 and a floor of -$1.8 million in Q4 2021.
Historically, Long-Term Debt Issuances has averaged $16.9 million across 3 years, with a median of $1.8 million in 2021.
The widest YoY moves for Long-Term Debt Issuances: up 4436.0% in 2022, down 103.57% in 2022.
Tracing TRIB's Long-Term Debt Issuances over 3 years: stood at $4.5 million in 2020, then tumbled by 139.03% to -$1.8 million in 2021, then skyrocketed by 103.57% to $63000.0 in 2022.
Business Quant data shows Long-Term Debt Issuances for TRIB at $63000.0 in Q4 2022, $80.0 million in Q1 2022, and -$1.8 million in Q4 2021.